key: cord-1030901-l33tpv54
authors: Huang, Yanting; Malcolm, Bruce A; Vederas, John C
title: Synthesis and testing of azaglutamine derivatives as inhibitors of Hepatitis A Virus (HAV) 3C proteinase
date: 1999-04-30
journal: Bioorganic & Medicinal Chemistry
DOI: 10.1016/s0968-0896(99)00006-1
sha: 7501758136e59d92ca0ae6ab34c1c2a030117fc5
doc_id: 1030901
cord_uid: l33tpv54

Abstract Hepatitis A virus (HAV) 3C proteinase is a picornaviral cysteine proteinase that is essential for cleavage of the initially synthesized viral polyprotein precursor to mature fragments and is therefore required for viral replication in vivo. Since the enzyme generally recognizes peptide substrates with l-glutamine at the P1 site, four types of analogues having an azaglutamine residue were chemically synthesized: hydrazo-o-nitrophenylsulfenamides A (e.g. 16); frame-shifted hydrazo-o-nitrophenylsulfenamides B (e.g. 25–28); the azaglutamine sulfonamides C (e.g. 7, 8, 11, 12); and haloacetyl azaglutamine analogues 2 and 3. Testing of these compounds for inhibition of the HAV 3C proteinase employed a C24S mutant in which the non-essential surface cysteine was replaced with serine and which displays identical catalytic parameters to the wild-type enzyme. Sulfenamide 16 (type A) showed no significant inhibition. Sulfenamide 27 (type B) had an IC50 of ca 100μM and gave time-dependent inactivation of the enzyme due to disulfide bond formation with the active site cysteine thiol, as demonstrated by electrospray mass spectrometry. Sulfonamide 8 (type C) was a weak competitive inhibitor with an IC50 of approximately 75μM. The haloacetyl azaglutamine analogues 2 and 3 were time-dependent irreversible inactivators of HAV 3C proteinase with rate constants k obs/[I] of 680M−1 s−1 and 870M−1 s−1, respectively, and were shown to alkylate the active site thiol. ©

The family of picornaviruses has more than 200 known members, divided into six genera, and contains pathogens such as poliovirus, human rhinovirus (HRV), encephalornyocarditis virus, foot and mouth disease virus and hepatitis A virus (HAV). 1±4 These viruses possess a positive single-stranded RNA genome whose translation in mammalian cells produces a large protein product. The co-and post-translational processing of this initial polyprotein relies on highly speci®c and organized cleavage by viral cysteine proteinases, which are attractive targets for development of therapeutic agents. 4,5 Among these, the 3C cysteine proteinases have been the subject of extensive structural investigation, with crystal structures reported for HAV 3C, 6, 7 HRV 3C, 8 and poliovirus 3C proteins. 9 Analogous 3C proteinases have also been detected in human and avian coronaviruses. 10, 11 These essential viral enzymes are especially appealing as targets for pharmaceutical intervention because their unique active site geometry 1 makes them highly speci®c in their choice of substrates and cleavage sites that are absent in non-infected mammalian cells. In addition, the active site residues appear to be relatively invariant in rhinovirus, where large numbers of serotypes (>100) make vaccine development dicult. 12 Structurally the 3C proteinases have topologies that resemble the two domain b-barrel fold of the chymotrypsin-like serine proteinases. 1,5±8 The active site cysteine (Cys-172 in HAV 3C) is in close proximity to a histidine residue (His-44 in HAV 3C) that acts as a general base to form the nucleophilic thiolate anion. Substrate recognition, by analogy to the chymotrypsin family, is believed to involve anti-parallel binding of the backbone of the peptide to the proteinase and the interaction of the side chains with the enzyme in several key subsites. Hydrogen-bonding between the carbonyl oxygen of the side chain of the P 1 glutamine of the substrate (or peptidic inhibitor) and a histidine at the S 1 subsite (His-191 in HAV 3C) is probably one of the key recognition events (1, 5±8). The wild type HAV 3C has 219 amino acids with a molecular weight of 24 kilodaltons and exists as an active monomer. For peptide substrates mimicking the 2B/2C junction of the large precursor polyprotein, the k cat of this enzyme is typically about 1.8 s À1 with a K m of 2.1 mM at a pH of 7.5. 5 In the search for therapeutic leads, enzyme inhibition studies on HAV 3C and HRV 3C proteins have employed a large variety of compounds, including peptide aldehydes, 13±15 peptide¯uoromethyl ketones, 16 b-lactams, 17 isatins, 18 homophthalimides, 19 vinylogous esters and sulfones, 12, 20, 21 and halomethyl carbonyl compounds. 22, 23 Some of these compounds do show in vitro antiviral activity in cell culture, 12,15,16,18±21 but toxicity can be a problem for substances that are generally reactive with thiols. 18 In the present study we examine a number of sulfurcontaining azaglutamine derivatives as potential inhibitors of HAV 3C proteinase. Incorporation of hydrazino functionality into peptide backbones (azapeptides) is well-established for generation of proteinase inhibitors, 24, 25 including cysteine proteinases. 26 Recently such analogues have been shown to act as active site titrants for cysteine proteinase, 27 and certain symmetrical bishydrazides are extremely potent nanomolar inhibitors of cathepsin K, a cysteine proteinase involved in boneremodeling. 28, 29 In one study on HRV 3C proteinase, an N-bromoacetyl azaglutamine dipeptide analogue 1 was shown to have an IC 50 of approximately 48 nM and to be a time-dependent irreversible inactivator with a k inact /K i value >2500 M À1 s À1 . 22 However, in this case the inhibitory activity depends on the highly reactive bromoacetyl moiety, which is likely to react non-speci-®cally with a variety of thiols present in mammalian cells. The amide character of sulfenamides and the use of aryl sulfenamides as amino acid protecting groups which are removable by thiols under acidic conditions (Scheme 1), 30±32 suggested that such functionality could display suciently low intrinsic reactivity and still form a disul®de with the active site thiol (Cys-172) of HAV 3C cysteine proteinase. Thus sulfenamide azaglutamine analogues of type A and B, as well as sulfonamide derivatives C, were synthesized and investigated for inhibition of this enzyme. Although the sulfonamides C would not be expected to react with the active site cysteine, they have some potential to bind to active site residues, and they also provide a new sulfur-containing aza analogue motif for investigation. The haloacetyl azaglutamine analogues 2 and 3 were also prepared for comparison. In each case the side chain amide functionality bears two methyls since such groups are wellaccepted by the HAV 3C enzyme and hinder interactions with possible reactive intermediates, especially at the P 1 carbonyl site. 13, 16, 33 Results and Discussion Synthesis and testing of peptidosulfonamides C Examination of structure C indicates that condensation of the known a-bromoketone 4 34,35 with the anion derived from sulfonamide 5 or 6 of b-alanine dimethylamide using the procedure of Jones 36 would aord the dipeptide analogues 7 or 8, respectively (Scheme 2). The required sulfonamides are readily available by deprotection of N-Boc-b-alanine dimethylamide 37 followed by reaction with the appropriate sulfonyl chloride. As expected, the condensation 36 with the bromoketone proceeds readily, and can be followed by hydrogenolysis to remove the Cbz group in quantitative yield and form the corresponding amino compounds 9 and 10. Studies on sequence recognition by HAV 3C proteinase using model peptides suggests that the P 4 residue should be a hydrophobic amino acid such as l-leucine, and that the P 2 and P 3 residues can be l-alanine. 38 This idea is supported by Scheme 1. inhibition of the enzyme at nanomolar levels by aldehyde and¯uoromethylketone peptide analogues that have such sequences. 13, 16 Thus coupling of 9 or 10 to Nacetyl-l-leucinyl-l-alanine proceeds readily with ethyl chloroformate to generate the target tetrapeptide azaglutamine sulfonamide derivatives 11 and 12.

Assay of the sulfonamides 7, 8, 11, and 12 for inhibition of HAV 3C proteinase employed a C24S mutant in which the non-essential surface cysteine was replaced with serine and which displays catalytic parameters indistinguishable from the wild-type enzyme. 16, 39 All of these compounds are weak competitive inhibitors, with 8 being the most potent with an IC 50 value of 75 mM. This is signi®cantly lower than the K m for an ideal hexapeptide substrate (2.1 mM), but not potent enough to warrant extensive study in view of the nanomolar inhibition achieved with a peptide aldehyde 13 and ā uoromethyl ketone. 16 The other sulfonamides had IC 50 values !100 mM.

For the synthesis of potential inhibitors with the structural framework A, Michael addition of hydrazine to N,N-dimethylacrylamide followed by protection of the more nucleophilic secondary nitrogen with benzyl chloroformate generates 13 along with the corresponding bisacylated product 14 (Scheme 3). Coupling of the free primary nitrogen with the tripeptide, N-acetyl-lleucinyl-l-alanyl-l-alanine proceeds smoothly to give 15. Hydrogenolytic deprotection liberates the alkylated nitrogen, which then immediately reacts with o-nitrosulfenyl chloride to aord the target sulfenamide 16. During these transformations it became clear that in the azaglutamine series, compounds which have amide character at only one nitrogen are prone to facile decomposition and should be protected at the other basic nitrogen as quickly as possible. Disappointingly, 16 shows no signi®cant inhibition (IC 50 >1 mM) of HAV 3C proteinase despite the presence of the P 4 -P 1 backbone. Not only is there no detectable reaction with the inhibitor, but the level of competitive binding at the active site is also very low. Presumably the aromatic sulfenamide moiety is too bulky to be easily accommodated in the enzyme site which binds the P 1 H substrate residue. Other sulfenamides were prepared wherein the o-nitrophenyl group is replaced with methyl or tri¯uoroethyl, but these compounds display very poor stability, especially in water, and were not pursued further.

The preparation of structural type B again begins with Michael addition of hydrazine to N,N-dimethylacrylamide, this time with protection of the central nitrogen with a tert-butoxycarbonyl group to generate 17 (Scheme 4). Reaction with benzyl chloroformate aords 18, which can then be deprotected with tri¯uoroacetic acid to liberate the secondary nitrogen and permit its acylation with a variety of protected amino acids and peptides. Such condensations aord azaglutamine derivatives 19±22. Because of the relative instability of the intermediate having the free basic nitrogen and solubility Scheme 2. problems with the N-acetyl-l-leucinyl-l-alanyl-l-alanine tripeptide, it proved advantageous to form tetrapeptide analogues via a two stage coupling. Thus compounds 21 and 22 were deprotected and coupled to the dipeptide, N-acetyl-l-leucinyl-l-alanine, to give 23 and 24, respectively. Hydrogenolytic removal of the Cbz groups of 19, 20, 23, and 24 followed by immediate reaction with o-nitrosulfenyl chloride yields the corresponding azaglutamine sulfenamide derivatives 25±28, respectively. These compounds all have a hydrazo nitrogen at the nominal position of the substrate P 1 carbonyl and sulfur at the P 1 H nitrogen site.

Assay of the type B compounds (i.e. 25±28) for inhibition of HAV 3C proteinase shows better binding than with the type A analogue 16, presumably because the frame shift on the peptide backbone allows the bulky o-nitrophenyl group to occupy a site further down the P H binding region in the enzyme active site. However, these substances still give only modest levels of inhibition with IC 50 values of 0.4 to 0.5 mM, with the exception of the tetrapeptide analogue 27, which has an initial IC 50 of ca 100 mM. Electrospray mass spectrometry of the C24S HAV 3C enzyme inhibited with 27 for a prolonged period (!3 h) does show formation of an enzyme-nitrophenyl disul®de, with the protein molecular ion peak shifting to higher mass by 1541 units (ÀH+C 6 H 4 NO 2 S). The relatively poor competition with substrate may again be due to unfavorable interactions of the aromatic portion of the inhibitor with the enzyme active site. Although the sulfenamide azapeptides are not as potent inhibitors of HAV 3C proteinase as the peptidic aldehydes 13±15 or¯uoromethyl ketone, 16 they represent new structural types that are reasonably accessible and stable, and may be useful for inhibition of other cysteine proteinases. Although additional thiols were not added to assay mixtures in the present study, and there is a possibility of non-speci®c reaction of compounds B and C with free thiols in vivo, removal of o-nitrophenylsulfenyl groups by extraneous thiols generally requires harsh conditions that include strong acid (e.g. p-toluenesulfonic acid) with high concentrations of thiol. 30±32 Cell culture studies could help to determine whether such sulfenamide functionalities are likely to be benign and stable in vivo.

Peptidic halomethyl carbonyl compounds are potent inactivators of 3C proteinases, 16, 22, 23 and as mentioned above, the bromoacetyl azaglutamine derivative 1 has been reported as an irreversible inhibitor of the HRV 3C enzyme. 22 The availability of precursors for aza analogues from our preceding work encouraged the construction of chloroacetyl and bromoacetyl azaglutamine derivatives 2 and 3, respectively (Scheme 5).

Thus reductive deprotection of 15 as in Scheme 3, followed by immediate acylation with chloroacetyl chloride or bromoacetyl bromide aords the target compounds directly. As expected, both 2 and 3 show potent time-dependent irreversible inhibition of HAV 3C proteinase with rate constants k obs /[I] of 680 M À1 s À1 and 870 M À1 s À1 , respectively. Electrospray mass spectrometry of the enzyme-inhibitor complexes show addition of 470 mass units to the molecular ion and suggest that in each case there is displacement of halogen by the active site thiol of Cys-172. This is in accord with the reaction of HAV 3C with a tetrapeptide¯uoromethyl ketone which has been studied by NMR spectrometry, 16 as well as with the displacement of halogen from iodoacetyl peptides by the active site thiol. 23, 40 Our compounds are somewhat less active against the HAV 3C enzyme than 1 is with the HRV 3C proteinase (k inact / K i value>2500 M À1 s À1 ). 22 The reasons for this are uncertain, but most likely re¯ect dierences between the proximal subsite interactions (P 1 and P 2 ) between the two enzymes with their cognate inhibitors. Possibly the presence of two methyl groups in the glutamine analogue side chain also has some eect. Moreover, it is clear that recognition of the peptide moiety in inhibitors 2 and 3 is crucial because the inherently more reactive compound, N-iodoacetamide, has a second order rate constant for inactivation of only about 3.1 M À1 s À1 . 23 In conclusion, the present work provides synthetic access to four types of aza amino acid peptide analogues. Although some show no binding (structural type A) or only weak initial inhibitory activity (structural types B and C) toward the hepatitis A virus 3C proteinase, the haloacetyl azaglutamine tetrapeptides 2 and 3 as well as the sulfenamide azaglutamine derivative 27 irreversibly react with the active site thiol (Cys-172). It is not unreasonable to expect that such substrate analogues may be more potent and useful for other types of cysteine proteinases. Current studies with other types of inhibitors of picornaviral proteinases will be reported shortly.

Most general procedures and instrumentation have been previously described. 41 Preparation, puri®cation and assays of HAV 3C (C24S) protein with and without inhibitors were done as previously reported. 13, 16 Purity of the enzyme samples was greater than 90% as determined by SDS-PAGE analysis. Proteinase concentrations were determined spectrophotometrically using e280=1.2 mg mL À1 . Enzyme activity was monitored using the trinitrobenzene sulfonate (TNBS) assay as previously described. 13, 16, 38 Reaction mixtures were incubated in reaction buer at 20 C. Aliquots (10 mL) were removed from the reaction mixture at timed intervals and peptide hydrolysis was quenched with 50 mL of 0.25 M sodium borate, pH 10. A solution (12.5 mL) of freshly prepared 0.14 M TNBS (Johnson±Matthey, Ward Hill,

MA) in 0.25 M sodium borate solution was added to the quenched reaction mixture and incubated for 10 min at 20 C. The color was stabilized by adding 200 mL of 3.5 mM Na 2 SO 3 , 0.2 M KH 2 PO 4 . The concentration of free amine generated during peptide hydrolysis was determined by measuring the absorbance at 405 nM using a microtitre plate reader (Biorad, Richmond, CA). Proteinase inactivation was quantitatively evaluated by progress curve analysis as previously described. 13 The extent of peptide proteolysis (release of a-amino groups) was monitored using the TNBS assay. The concentrations of potential inhibitors were varied from 0.5 to 500 mM; substrate (Ac-ELRTQSFS-amide) concentration was 2 mM and HAV-3C proteinase (C24S mutant) concentration was 0.07 mM. Enzyme was dialyzed against reaction buer to remove DTT immediately prior to use. Reactions were initiated with enzyme and absorbances were converted into mmoles of product using a glycine standard curve. All determinations were performed in triplicate with dierent enzyme and inhibitor preparations. Progress curves were ®tted using least squares non-linear regression analysis using Mac Curve Fit 1.0.7, (K. Raner):

where n o is the initial velocity and k is the apparent ®rst order rate constant (k obs ) for the inactivation process. The weighted average of parameter estimates from a minimum of three individual experiments was used to calculate reported rate constants.

General peptide synthesis and puri®cation procedures have been described earlier, 16 and employed a Rainin PS-3 solid-phase peptide synthesizer using standard Fmoc chemistry on Wang Resin. All peptides were puri®ed by reverse-phase HPLC (C-18, 5Â25 cm, Vydac, 2%/min linear gradient of 0.1% TFA/water adding 0.1% TFA/acetonitrile). Peptide structures were veri®ed by NMR and mass spectrometry. In cases where restricted rotation around amide bonds generates conformers detectable by NMR spectrometry, high temperature studies were done to demonstrate equilibria and coalescence of resonances. Mass spectrometry of enzyme-inhibitor complexes employed instrumentation and methodology speci®ed in preceding publications. 13,23 Triethylamine (0.90 mL, 6.00 mmol) was added dropwise to a stirred solution of this amine salt (1.15 g, 5.00 mmol) in dry CH 2 Cl 2 (20 mL) under argon at 0 C. The mixture was stirred at 0 C for 5 min, and then methanesulfonyl chloride (0.39 mL, 5.00 mmol) and triethylamine (0.90 mL, 6.00 mmol) were added dropwise. The reaction mixture was stirred at 0 C for 2 h, and then concentrated in vacuo. EtOAc (150 mL) was added to the residue, and the precipitate was removed by ®ltration. The ®ltrate was washed with water (20 mL), saturated aq NaHCO 3 (20 mL) and brine (50 mL), and dried (Na 2 SO 4 ). The solvent was removed in vacuo to give an oil. Puri®cation by¯ash chromatography (ethyl acetate) gave the sulfonamide 5 (0.65 g, 67%) as an oil: IR (CH 2 

propanamide (6) . The procedure for preparation of 5 was employed to react amine salt (1.15 g, 5.00 mmol) obtained by deprotection of Boc-b-alanine dimethylamide, 37 triethylamine (1.8 mL, 12.00 mmol) and ptoluenesulfonyl chloride (0.95 g, 5.00 mmol) to give the previously reported 43 (7). To a stirred solution of sulfonamide 5 (0.82 g, 4.2 mmol) in anhydrous DMF (10 mL) under argon at 0 C, was added NaH (60% dispersion in mineral oil) (0.237 g, 5.9 mmol) in small portions, and the mixture was stirred at 0 C for an additional 30 min. The resulting yellow anion solution was added dropwise over a 30 min period to a stirred solution of bromo compound 4 34,35 (1.51 g, 5.0 mmol) in DMF (5 mL). After 1 h at room temperature, the solvent was removed in vacuo, and the residue was dissolved in CH 2 Cl 2 , and washed with 1% aq HCl (10 mL), 5% aq NaHCO 3 (10 mL) and brine (10 mL). The organic phase was dried (Na 2 SO 4 ) and concentrated in vacuo to give an oil. (8) . The procedure used for the preparation of 7, was employed to condense sulfonamide 6 (1.00 g, 3.7 mmol) and bromomethyl ketone 4 34, 35 (10) . The procedure used for the preparation of 9, was adapted to convert N-Cbz sulfonamide 8 (0.500 g, 1.02 mmol) with 10% palladium on charcoal (50 mg (11) . A solution of the dipeptide Ac-Leu-Ala-OH (0.216 g, 0.89 mmol) in dry THF (10 mL) under argon at 0 C was treated with ethyl chloroformate (90 mL, 0.89 mmol) and triethylamine (0.13 mL, 0.91 mmol) and stirred for 20 min. A solution of sulfonamido amine hydrochloride 9 (0.280 g, 0.89 mmol) in THF (5 mL), and triethylamine (0.13 mL, 0.91 mmol) were added, and the reaction mixture was stirred for 30 min. It was then allowed to warm to room temperature and stirred overnight. To the mixture was added EtOAc (40 mL), and the organic phase was washed with saturated aq NaHCO 3 (20 mL) and brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to give the crude product 11. Puri®cation by HPLC (linear gradient elution over 25 20, 175.37, 175.32, 173.83, 173.28, 55.22, 54.12, 54.02, 50.65, 46.19, 40.14, 39.49, 38.86, 36.38, 34.12, 25.67, 22.80, 22.39, 21.97, 19.39, 15.76 ; MS (FAB) 506.3 (80) (MH + ). (12) . The procedure used for the preparation of 11, was used to condense dipeptide Ac-Leu-Ala-OH (0.156 g, 0.64 mmol) and sulfonamido amine hydrochloride 10 (0.250 g, 0.64 mmol) in the presence of ethyl chloroformate (62 mL, 0.64 mmol) and triethylamine (0.178 mL, 1.28 mmol). Puri®cation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 30% to 50%, t R 15.8 min) gave the title compound 12 (0.208 g, 56%) as a solid. Spectral characterization showed a mixture of conformers (13) . N,N-Dimethylacrylamide (4.96 g, 50 mmol) was added dropwise to a solution of hydrazine monohydrate (2.50 g, 50 mmol) in MeOH (30 mL). The reaction mixture was stirred at room temperature for 2 h, diluted with MeOH (30 mL), dried (Na 2 SO 4 ), and then concentrated in vacua to give crude 3-hydrazino-N,N-(dimethyl)propanamide (6.5 g). A stirred solution of this compound (2.62 g, 20 mmol) in a mixture of diethyl ether (30 mL), water (15 mL) and 1 N NaOH (20 mL) was cooled in an ice-bath. Benzyl chloroformate (2.8 mL, 20 mmol) was added and stirring was continued in the ice-bath for 1 h. The precipitate was ®ltered, the ®ltrate was concentrated in vacuo to 20 mL, and then extracted with ethyl acetate (3Â80 mL). The combined organic extracts were washed with brine (20 mL), dried (Na 2 SO 4 ) and the solvent was concentrated in vacua to give an oil. Puri®cation by¯ash chromatography (ethyl acetate:methanol, 95:5) gave the desired 13 (1.59 g, 30%) (15) . To a solution of tripeptide Ac-Leu-Ala-Ala-OH (0.315 g, 1 mmol), Cbz hydrazino derivative 13 (0.265 g, 1 mmol) and benzotriazolyl-N-oxytris(dimethylamino)phosphonium hexa¯uorophosphate (BOP) (0.442 g, 1 mmol) in DMF (10 mL) was added triethylamine (0.139 mL, 1 mmol). The mixture was stirred at room temperature for 6 h, and then concentrated in vacuo to give an oil. To a solution of Cbz derivative 15 (56.2 mg, 0.10 mmol) in methanol (10 mL) under argon was added 10% palladium on charcoal catalyst (10 mg). The mixture was stirred under an atmosphere of hydrogen until gas absorption ceased. The catalyst was removed by ®ltration through a column of Celite, and the ®ltrate was concentrated in vacuo to give the unstable deprotected hydrazine (42.8 mg, quantitative). To a stirred solution of this crude material (42.8 mg, 0.10 mmol) and o-nitrophenylsulfenyl chloride (18.9 mg, 0.10 mmol) in DMF (1 mL) under argon, at À10 C, was added triethylamine (14 mL, 0.10 mmol). After 30 min at À10 C, the reaction mixture was allowed to warm to room temperature and was stirred for 1 h. The solution was then concentrated in vacuo. Puri®cation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 25% to 40%, t R 10.6 min) gave the title compound 16 (37.8 mg, 65%) as a yellow powder. Spectral characterization indicated a mixture of conformers (conformer A:conformer B, 5: 

(3S)-{N 1 -[3 H -(N,N-Dimethylamino)-3 H -oxopropyl]-N 1 -(p- methylphenylsulfonyl)}-1,3-diaminobutan-2-one hydrochlo- ride

3 -[N 1 -(Benzyloxycarbonyl)hydrazino] -N,N -(dimethyl) - propanamide

propanamide (17) . A stirred solution of the crude 3hydrazino-N,N-(dimethyl)propanamide (2.62 g, 20 mmol), which was obtained as in the preparation of 13, in a mixture of dioxane (30 mL), water (15 mL) and 1 N NaOH (20 mL) was cooled in an ice-bath. Di-tert-butyl pyrocarbonate (4.8 g, 22 mmol) was added and stirring was continued at room temperature for 1 h. The precipitate was ®ltered, the ®ltrate was concentrated in vacuo to 25 mL, and then extracted with ethyl acetate (3Â80 mL). The combined organic extracts were washed with brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to give an oil. (18) . To a suspension of Boc-propanamide 17 (2.31 g, 10 mmol) and anhydrous potassium carbonate (6.91 g, 50 mmol) in dry THF (20 mL), was added benzyl chloroformate (1.88 g, 11 mmol) with vigorous stirring. The mixture was heated to 40±50 C for 2 h. The precipitate of KHCO 3 and K 2 CO 3 was removed by ®ltration. The ®ltrate was concentrated in vacuo. The residue was dissolved in ethyl acetate (100 mL), washed with 1 N NaHCO 3 (20 mL), water (20 mL) and brine (20 mL), dried (Na 2 SO 4 ) and concentrated in vacuo to give an oil. 3-[N 1 -(Acetyl-D-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (19) . To a stirred solution of Boc derivative 18 (1.10 g, 3 mmol) in dry CH 2 Cl 2 (10 mL) under argon, was added tri¯uoroacetic acid (10 mL). The solution was stirred at room temperature for 2 h and was then concentrated in vacuo. Toluene (10 mL) was added, and the mixture was concentrated in vacuo. The residue was dried in vacuo overnight to give the crude unstable hydrazino compound. This was dissolved in dry THF (3 mL), and triethylamine (1.57 mL, 10.5 mmol) was added to form the amine solution A. A solution of N-acetyl-d-alanine (0.393 g, 3.0 mmol) in dry THF (10 mL) was cooled to À5 C with stirring under argon. Triethylamine (0.45 mL, 3.0 mmol) and ethyl chloroformate (0.29 mL, 3.0 mmol) were added. The mixture was stirred for 20 min at À5 C, then the amine solution A was added. After 30 min at À5 C, the reaction mixture was allowed to warm to room temperature and stirred for 2 h. The precipitate was ®ltered and the ®ltrate was concentrated in vacuo. The residue was dissolved in ethyl acetate (100 mL), washed with said aq NH 4 Cl (15 mL), 1 N NaHCO 3 (15 mL) and brine (15 mL), dried (Na 2 SO 4 ) and concentrated in vacua to give an oil. (20) . The procedure used for the preparation of 19 was adapted to prepare the tri¯uoroacetate salt (1.14 g, 3 mmol) and condense it with N-acetyl-l-alanine (0.393 g, 3 mmol) to give 20 (0.86 g, 76%) as a gum: IR (CH 2 3-[N 1 -(tert-Butyloxycarbonyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (21) . The above procedure for the preparation of 19, was adapted to prepare and condense the tri¯uoroacetate salt (0.376 g, 1 mmol) and N-t-Boc-l-alanine (0.131 g, 1 mmol) to give 21 (0.350 g, 80%) as a colorless oil: IR (CH 2 3-[N 1 -(tert-Butyloxycarbonyl--alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (22) . The procedure used for the preparation of 19, was adapted to prepare and convert the tri¯uoroacetate salt (2.93 g, 7.8 mmol) and N-t-Boc-b-alanine (1.47 g, 7.8 mmol) to 22 (2.14 g, 63%) as an oil: IR (CH 2 3-[N 1 -(Acetyl-L-leucyl-L-alanyl-L-alanyl)-N 2 -(benzyloxycarbonyl)hydrazino]-N,N-(dimethyl)propanamide (23). The above procedure for the preparation of 19, was adapted to convert 21 (0.130 g, 0.3 mmol) and Ac-Leu-Ala-OH (73.2 mg, 0.3 mmol) to the crude product. This was puri®ed by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 20% to 40%, t R 12.8 min) to give 23 (0.118 g, 70%) as a white solid: mp 183±184 C; IR (CH 2 

This was puri®ed by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 20% to 40%, t R 14.2 min) to give 24 (0.110 g, 65%) as a white solid: mp 156±158 C; IR (CH 2 Cl 2 cast) 3289

The mixture was stirred under an atmosphere of hydrogen until absorption of gas ceased. The catalyst was removed by ®ltra-tion through a column of Celite and the ®ltrate was concentrated in vacuo to give 3-[N H -(acetyl-d-alanyl)-hydrazinol-N,N-(dimethyl)propanamide (0.244 g, quantitative) as a colorless oil: IR (CH 2 Cl 2 cast) 3314, 3214, 2934, 1636, 1542 cm À1 ; 1 H NMR (360 MHz

33 mmol) and o-nitrophenylsulfenyl chloride (62.9 mg, 0.33 mmol) in DMF (2 mL) under argon, at À10 C, was added triethylamine (50 mL, 0.33 mmol). After 30 min at À10 C, the reaction mixture was allowed to warm to room temperature, and was then stirred for 1 h. The solution was concentrated in vacuo. Puri®cation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 25% to 45%,¯ow rate 15.0 mL min À1 , t R 11.6 min) gave the title compound 25 (0.108 g, 82%) as a yellow powder

Cl 2 cast) 3283

95 (s, 3H, NCH 3 ), 2.92 (s, 3H, NCH 3 ), 2.75±2.67 (m, 2H, CH 2 CO), 1.88 (s, 3H, COCH 3 ), 1.17 (d, 3H, J=6.8 Hz, CH 3 Ala); (conformer B) d 8

The above procedure for the preparation of 25 was used with Cbzhydrazino derivative 20 (0.378 g, 1 mmol) to give the intermediate 3-[N 1 -(acetyl-lL-alanyl)hydrazino]-N,N-(dimethyl)propanamide (0.243 g, quantitative) as a colorless oil: IR (CH 2 Cl 2 cast) 3312, 3213, 2933, 1633, 1541 cm À1 ; 1 H NMR (300 MHz

MS (FAB) 245.2 (100) (MH + )

mg, 0.41 mmol) and triethylamine (57.2 mL, 0.41 mmol) were reacted as above to give the crude product

95 (s, 3H, NCH 3 ), 2.92 (s, 3H, NCH 3 ), 2.71 (t, 2H, J=5.5 Hz, CH 2 CO), 1.88 (s, 3H, COCH 3 ), 1.16 (d, 3H, J=6.8 Hz, CH 3 ); (conformer B) d 8

The procedure used for the preparation of 16, with Cbz-hydrazino derivative 23 (58.2 mg, 0.10 mmol) and 10% palladium on charcoal catalyst (10 mg) in methanol (10 mL), followed by o-nitrophenylsulfenyl chloride (18.9 mg, 0.10 mmol) gave the crude product 27. Pur-i®cation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 25% to 40%, t R 15.6 min) gave the title compound 27 (29.1 mg, 50%) as a yellow powder

Cl 2 cast) 3284

CD 3 OD) (conformer A)

(m, 2H, NCH 2 ), 3.01 (s, 3H, NCH 3 ), 2.91 (s, 3H, NCH 3 ), 2.80± 2.70 (m, 2H, COCH 2 ), 1.98 (s, 3H

The procedure used for the preparation of 16, was employed with Cbz-hydrazino derivative 24 (58.2 mg, 0.10 mmol) and 10% palladium on charcoal catalyst (10 mg) in methanol (10 mL), followed by o-nitrophenylsulfenyl chloride (18.9 mg, 0.10 mmol) to give the crude product 28. Puri®cation by HPLC (linear gradient elution over 20 min of acetonitrile and water, from 25% to 40%, t R 17.5 min) gave the title compound 28 (35 mg, 60%) as a yellow powder

1337 cm À1 ; 1 H NMR (300 MHz

90 (s, 3H, NCH 3 ), 2.86 (s, 3H, NCH 3 ), 2.82±2.65 (m, 4 H, 2 COCH 2 ), 1.96 (s, 3H

Proteinases of Infectious Agents

701±754. (b) Rasnick, D. Perspectives in Drug Discovery and Design

Marakovits

For discussion and leading references to azapeptides see

For an example of an orally-available azapeptide inhibitor of HIV-1 protease see: FaÈ ssler

For related work using amino ketones see

Protective Groups in Organic Synthesis

A preliminary portion of this work has been mentioned in a recent review but without experimental detail

A crystal structure of HAV 3C with N-iodoacetyl-Val-Phe-NH 2 , has been solved by

The authors would like to thank: Drs. Michael N. James and Ernst M. Bergmann (Biochemistry Department, University of Alberta) for many helpful discussions and suggestions. Colin Luo and Shirley Shechosky are gratefully acknowledged for extensive assistance with enzyme assays. These investigations were supported by the US National Institutes of Health (Grant AI 38249) and the Natural Sciences and Engineering Research Council of Canada.